Table 3 .
Design of randomised controlled trials and selected baseline characteristics of eligible trials of calcium supplements that also used vitamin D supplements
Trial | Design | Calcium dose (mg/d) | Vitamin D dose (IU/d) | Duration | Care setting | No of participants* | No in Ca/control group† | % women | Mean age (y) |
---|---|---|---|---|---|---|---|---|---|
Smith 198133 | 2×2 factorial: CaD, ex, ex/CaD, P | 750 | 400 | 3 y | Institution | 80 | 21/30 | 100 | 82 |
Orwoll 199038 | 2 arm: CaD , P | 1000 | 1000 | 3 y | Community | 86 | 41/36 | 0 | 58 |
Chapuy 199241 | 2 arm: CaD, P | 1200 | 800 | 18 mo | Institution | 3270 | 27/29 | 100 | 84 |
Aloia 199444 | 3 arm: CaD, HRT/CaD, P/D | 600 | 400 | 2.9 y | Community | 118 | 34/36 | 100 | 52 |
Chevalley 199419 | 3 arm: CaD, OMC/D, P/D | 800 | 300 000 IM stat | 18 mo | Community | 93 | 31/31 | 89 | 72 |
Dawson-Hughes 199749 | 2 arm: CaD, P | 500 | 700 | 3 y | Community | 445 | 187/202 | 55 | 71 |
Baeksgaard 199850 | 3 arm: CaD, CaD/multivitamins, P | 1000 | 560 | 2 y | Community | 160 | 65/63 | 100 | 62 |
Chapuy 200256 | 3 arm: CaD, CaD, P | 1200 | 800 | 2 y | Institution | 610 | 393/190 | 100 | 85 |
Grados 200357 | 2 arm: CaD, P | 500 | 400 | 12 mo | Community | 192 | 95/97 | 100 | 75 |
Doetsch 200458 | 2 arm: CaD, P | 1000 | 800 | 12 w | Community | 30 | 16/14 | NS | NS |
Harwood 200414 | 4 arm: CaD, CaD, D, control | 1000 | 300 000 IM stat or 800 | 12 mo | Community | 150 | 75/75 | 100 | 81 |
Meier 200459 | 2 arm: CaD, control | 500 | 500 | 6 mo | Community | 55 | 27/16 | 67 | 56 |
Riedt 200560 | 3 arm: CaD/w-loss, D/w-loss, w-maintain | 1200 | 400 | 6 mo | Community | 55 | 23/24 | 100 | 61 |
Jackson 20067 | 2 arm: CaD, P | 1000 | 400 | 7 y | Community | 2431 | 1230/1201 | 100 | 62 |
Bolton-Smith 200763 | 2×2 factorial: CaD, CaD/vit K, vit K, P | 1000 | 400 | 2 y | Community | 244 | 99/110 | 100 | 68 |
Bonnick 200764 | 3 arm: CaD/alend, CaD, alend/D | 1000 | 400 | 2 y | Community | 563 | 282/281 | 100 | 66 |
Hitz 200715 | 2 arm: CaD, P | 1200 | 1400 | 12 mo | Community | 122 | 34/45 | 83 | 68 |
Zhu 200866 | 3 arm: Ca, CaD, P | 1200 | 1000 | 5 y | Community | 120 | 79/41 | 100 | 75 |
Karkkainen 201069 | 2 arm: CaD, control | 1000 | 800 | 3 y | Community | 593 | 287/306 | 100 | 67 |
Ca=calcium; HRT=hormone replacement therapy; P=placebo; CaD=co-administered calcium and vitamin D; ex=exercise; OMC=ossein-mineral complex; D=vitamin D; IM=intramuscular; w-loss=weight loss, w-maintain=weight maintenance; vit K=vitamin K; alend=alendronate; NS=not stated.
*Total number of randomised participants in all treatment arms.
†Number of participants in relevant arms from trial in whom bone mineral density was reported.